Not Signed In - Human Genome Sciences Reports Positive Interim Results Of Phase 2 Trials Of Albuferon(TM) With Ribavirin In Patients With Chronic Hepatitis C
Wed, 01 Nov 2006 08:00 AM EST
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported the interim results of two Phase 2 clinical trials to evaluate the efficacy and safety of Albuferon(TM) (albumin- interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C. [click link for full article] ...
Related Topics
- Genes and Gene Therapy
- Hepatitis C
- Hepatitis B
- Hepatitis A
- Human Genome Epidemiology Network
- Hepatitis
- Autoimmune Hepatitis
- Hepatitis A and Hepatitis B Vaccine
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Hepatitis A Vaccine
- Human Papilloma Virus
- Hepatitis B Vaccine
- Clinical Trials
- Hepatitis B Immune Globulin
- Chronic Fatigue Syndrome
- Growth Hormones
- Growth Hormone
- Pain - Chronic
- Chronic Pain
email this page
print this page
bookmark this page
feedback on this page
